Hinokitiol inhibits RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced bone loss in vivo
Authors:
- 1 July 2021
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 96, 107619
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81871801, 82072467, LQ21H060001)
- Natural Science Foundation of Zhejiang Province (81871801, 82072467, LQ21H060001)
This publication has 40 references indexed in Scilit:
- Erk1 Positively Regulates Osteoclast Differentiation and Bone Resorptive ActivityPLOS ONE, 2011
- The Role of Osteoclast-Associated Receptor in OsteoimmunologyThe Journal of Immunology, 2011
- NF-κB modulators in osteolytic bone diseasesCytokine & Growth Factor Reviews, 2009
- Hinokitiol, a Natural Tropolone Derivative, Inhibits TNF-α Production in LPS-Activated Macrophages via Suppression of NF-κBPlanta Medica, 2008
- NFATc1 Induces Osteoclast Fusion Via Up-Regulation of Atp6v0d2 and the Dendritic Cell-Specific Transmembrane Protein (DC-STAMP)Molecular Endocrinology, 2008
- Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitroBone, 2007
- Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNature Reviews Immunology, 2007
- RANKL–RANK signaling in osteoclastogenesis and bone diseaseTrends in Molecular Medicine, 2006
- Osteoclast differentiation and activationNature, 2003
- Receptor Activator of NF-κB Ligand (RANKL) Activates TAK1 Mitogen-Activated Protein Kinase Kinase Kinase through a Signaling Complex Containing RANK, TAB2, and TRAF6Molecular and Cellular Biology, 2002